| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
2 companies
James Hassard last filed a Form 4 in July 2024, as Chief Commercial Officer at ARWR. The filings on record cover 2 companies. James Hassard's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, James Hassard's trades have earned a middling insider score of 61/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +44.0%.
At the last filing, the largest reported position was 105,750 shares of ARWR. The ARWR filings lean toward selling, a net 19,250 shares.
James Hassard has 8 Form 4 filings on record from January 2021 to July 2024, across 2 companies: Chief Commercial Officer at Crinetics Pharmaceuticals (CRNX), 2022–2024; Chief Commercial Officer at Arrowhead Pharmaceuticals (ARWR), 2021.
The 12 reported transactions were 4 open-market sales, 3 option or other derivative awards, 2 option exercises and 2 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $2.8M.
The largest open-market sale was 15,625 shares of ARWR at an average $75.00 on January 7, 2021, about $1.2M.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from July 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 5, 2024 | CRNX Crinetics Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 15,000 | $44.08 | $661,200.00 | -33.9% | +20.4% | -33.7% | |
| Jun 21, 2024 | CRNX Crinetics Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 15,000 | $44.66 | $669,900.00 | -33.9% | +18.2% | -33.8% | |
| Jun 22, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 3,625 | $89.22 | $323,422.50 | -3.3% | -29.8% | -64.5% | |
| Jan 7, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 15,625 | $75.00 | $1,171,875.00 | -12.5% | - | - |